Acetaminophen: profile and news

Sanofi-Aventis announces gross profits of €5,442 million in Q4 ... 06 Mar 2006
Mr. Jean-François Dehecq said: “Barring major adverse events, and after taking account of the full-year impact of generics of Allegra, Amaryl, Arava, and ... - Strategiy,

FDA decision on Sanofi obesity pill weighs on shares Feb 25, 2006
In the second half of last year two of its bestsellers, Allegra and Amaryl, faced generic competition for the first time. Sales fell sharply. ... - Business Online,

Sanofi-aventis Reports Strong Growth of 25.7% in 2005 Adjusted EPS ... Feb 24, 2006
CEO Mr Jean-Francois Dehecq said: "Barring major adverse events, and after taking account of the full-year impact of generics of Allegra(R), Amaryl(R), Arava(R ... - PR Newswire (press release),

Medco Reports Fourth Quarter 2005 GAAP EPS of $0.57, Up 18.8 ... Mar 1, 2006
54.6 percent, up 4.6 percentage points from the same period last year due primarily to the recent availability of Zithromax(R), Allegra(R), and Amaryl(R) in ... - MSN Money

Sanofi-Aventis' Battered Charm Mar 1, 2006
The company's fourth-quarter 2005 sales were slightly below our projections, with generics affecting sales of Allegra antihistamine and Amaryl treatment for ... - BusinessWeek

Sanofi-aventis Reports Strong Growth of 25.7% in 2005 Adjusted EPS ... Feb 24, 2006
Mr Jean-Francois Dehecq said: "Barring major adverse events, and after taking account of the full-year impact of generics of Allegra®, Amaryl®, Arava®, and ... - Yahoo! News (press release)

Shire plc: Strong 2005 Performance Supports Positive Outlook Feb 23, 2006
...hydrochloride) The following are trademarks of third parties referred to in this press release: 3TC (trademark of GlaxoSmithKline (GSK)) AMARYL (trademark of ... - PR Newswire (press release),

Avandaryl: New Combined Drug for Type 2 Diabetes Feb 8, 2006
Avandaryl is the first and only tablet to combine a thiazolidinedione - know as Avandia - with a sulfonylurea, glimepiride - known as Amaryl - to help improve ... - About - News & Issues,

Medco Reports Fourth Quarter 2005 GAAP EPS of $0.57, Up 18.8 ... Mar 1, 2006
...percent, up 4.6 percentage points from the same period last year due primarily to the recent availability of Zithromax®, Allegra®, and Amaryl® in generic ... - Yahoo! News (press release)

FDA Approves GSK Diabetes Combination Therapy Feb 4, 2006
Avandaryl combines Avandia and Amaryl, two other diabetes drugs for the control of blood sugar levels. As an adjunct to diet and ... - International News Service,

GlaxoSmithKline launches Avandaryl Feb 1, 2006
The treatment, which combines the company's diabetes treatments Avandia and Amaryl, received Food and Drug Administration approval in December. ... - BusinessWeek

Glaxo's Type 2 diabetes combo drug OK'd Feb 1, 2006
...into one tablet two already-marketed Glaxo products, Avandia -- thiazolidinedione (TZD), rosiglitazone maleate -- and Amaryl -- sulfonylurea glimepiride. ... - United Press International

Sanofi to Introduce Acomplia as Diet Pill This Year (Update3) Feb 23, 2006
Sales from diabetes drug Amaryl, which lost patent protection in October, slid 29 percent to 135 million euros in the fourth quarter, the company said last ... - Bloomberg

France's Sanofi-Aventis reports 26 percent profit rise in 2005 Feb 24, 2006
...billion dollars) in sales for the full year because of competition from generics, especially for allergy treatment Allegra, diabetes treatment Amaryl and DDAVP ... - People's Daily Online,

Shire Plc: Strong 2005 Performance Supports Positive Outlook Feb 23, 2006
...worked closely with the FDA on a name change following dispensing errors in the US, between REMINYL and the Type 2 diabetes mellitus drug known as AMARYL. ... - International News Service,

Type 2 Diabetes - GSK Announces Approval And Availability Of ... Feb 2, 2006
...a thiazolidinedione (TZD), rosiglitazone maleate - separately marketed as Avandia(R) - with a sulfonylurea, glimepiride - separately marketed as Amaryl(R) - to ... - Medical News Today (press release),

Sanofi 4Q overshadowed by impending legislation Feb 1, 2006
The generically-challenged diabetes drug Amaryl was up 1 per cent to $818 million for the year, but fourth quarter sales sank by 29 per cent to $163 million. ... - In-PharmaTechnologist.com,

Sanofi expects Acomplia launch in 06; profits up Feb 24, 2006
...this year, held back by the onset of generic competition to four products, the antihistamine Allegra (fexofenadine), diabetes drug Amaryl (glimepiride), Arava ... - Pharma Times (subscription),

FDA approves GSK diabetes combination therapy Feb 2, 2006
By Staff Writer. Avandaryl combines Avandia and Amaryl, two other diabetes drugs for the control of blood sugar levels. As an adjunct ... - Pharmaceutical Business Review

Sanofi-Aventis: strong sales before generics gloom Feb 2, 2006
US. However, these encouraging performances were partially offset by generic competition to key products Allegra and Amaryl. Looking ... - Pharmaceutical Business Review

GSK debuts Avandaryl for diabetes in the USA Feb 2, 2006
Avandaryl is based on GSK's Avandia (rosiglitazone maleate) and the active ingredient in Sanofi-Aventis' Amaryl (glimepiride), now generically available in the ... - Pharma Times (subscription),

Business briefs Feb 18, 2006
Sanofi is counting on new products such as Acomplia as the company faces the loss of patent protection on drugs such as the Amaryl diabetes treatment, which ... - NorthJersey.com,

Healthcare: MSD Readies Ground for Diabetes Launch Feb 17, 2006
Last week GlaxoSmithKlein launched Avandaryl in the US. It is the first tablet treatment to combine commonly prescribed Avandia and Amaryl. ... - International News Service,

GSK's lung cancer drug Hycamtin gets European OK Feb 1, 2006
The product is a combination of GSK's Avandia and Sanofi-Aventis SA's Amaryl. At 11.00 am GSK shares were trading 11 pence higher at 1449. - Forbes

New Type 2 Diabetes Drug Hits Market Feb 1, 2006
...market. The drug, called Avandaryl, combines two other diabetes drugs -- Avandia and Amaryl -- to help improve control of blood sugar. ... - FOX News

Sanofi-Aventis quarterly sales slow Jan 30, 2006
French drugmaker Sanofi-Aventis said Monday that quarterly sales growth slowed on generic competition for its Allegra allergy drug and its Amaryl diabetes drug ... - Investor's Business Daily (subscription)

Sanofi-Aventis ups earnings view; sales growth slows Jan 30, 2006
...in ahead of its earlier target, but said fourth-quarter sales growth slowed on generic competition for its Allegra allergy drug and its Amaryl diabetes drug. ... - Investor's Business Daily (subscription)

Sanofi-Aventis FY sales 27.311 bln eur, up 9.3 pct; raises FY ... Jan 29, 2006
Excluding the impact of genetic versions of Allegra and Amaryl in the US, sales growth of the top 15 products would have been 16.8 pct. ... - Forbes

Generics eat into Sanofi-Anventis sales Jan 30, 2006
New generic rivals to four blockbuster drugs, including the hayfever drug Allegra and diabetes treatment Amaryl, also cramped sales in the US, which account ... - MSN Money

Sanofi-aventis Posts Dynamic Growth in 2005 Full-Year Consolidated ... Jan 30, 2006
Excluding the impact of generics of Allegra® and Amaryl® in the United States, growth for the top 15 products would have reached 15.7%. ... - Yahoo! News (press release)

New Analysis: Recent Generic Blockbusters Show Huge Gains ... Jan 18, 2006
...total generic dispensing rates for Allegra(R), Arava(R), Amaryl(R), and Zithromax(R), topped 87 percent within 30 days after the brand-name counterparts ... - PharmaLive.com (press release),

Study finds 87% of consumers are switching to generic drugs Jan 18, 2006
The analysis of four drugs - Allegra, Arava, Amaryl and Zithromax - each of which lost patent protection in the second half of 2005, showed that generic ... - NorthJersey.com,

Sanofi Q4 sales up 7 pct, raises 2005 EPS forecast Jan 29, 2006
...in September. Generic rivalry in the last quarter also kicked in for arthritis treatment Arava and diabetes drug Amaryl. Growth ... - MSN Money

Sanofi raises growth goal, obesity pill on track Jan 30, 2006
Generic rivalry also kicked in during the quarter for diabetes drug Amaryl, which ranks among Sanofi's top 15 products, and arthritis treatment Arava. - Reuters

US stocks to open lower; Exxon Mobil up on earnings Jan 30, 2006
Sanofi-Aventis (SNY) reported a slowdown in quarterly sales growth due to generic competition for its Allegra allergy drug and its Amaryl diabetes drug. ... - Investor's Business Daily (subscription)

Updates, advisories and surprises Jan 30, 2006
Generic versions of Allegra pulled sales of that drug down 58.5% on a comparable basis to 160 million euros, and generic Amaryl drug sales pulled its sales ... - Investor's Business Daily (subscription)

Top drugs help Sanofi-Aventis weather generic impact in Q4 Jan 30, 2006
Generic competition also bit into sales of diabetes drug Amaryl (glimepiride), which slumped 29% to 135 million euros in the quarter. ... - Pharma Times (subscription),

Pfizer's Zithromax Loses Prescriptions to Generics, Medco Says Jan 17, 2006
The three other drugs Medco examined are Sanofi-Aventis SA's Allegra for allergies, Arava for rheumatoid arthritis and Amaryl for diabetes. ... - Bloomberg

Industry Insider: Waning shipments force drug importer to shut ... Jan 18, 2006
...other medicines scrutinized were generic versions of the Allegra allergy pill; Arava, a treatment for rheumatoid arthritis, and the Amaryl diabetes medication. - Newark Star Ledger,

Health Professionals and Consumers Accept Generic Blockbusters Jan 18, 2006
6, 2005. The diabetes treatment Amaryl reached US sales of $277 million in 2004, with the generic version receiving FDA approval on October 7, 2005. ... - PharmaLive.com (press release),

Other information

Indication
For the treatment of mild to moderate pain, and fever reducing agent

Pharmacology
Acetaminophen, a para-aminophenol analgesic, is the active metabolite of phenacetin. Although, Acetaminophen's analgesic and antipyretic activity is similar to aspirin, Acetaminophen has no peripheral anti-inflammatory activity or effects on platelet function. Acetaminophen is used to treat both acute and chronic pain, on its own or in combination with pseudoephedrine, dextromethorphan, chlorpheniramine, diphenhydramine, doxylamine, codeine, hydrocodone, or oxycodone.

Mechanism Of Action
Acetaminophen is thought to act primarily in the CNS, increasing the pain threshold by inhibiting both isoforms of cyclooxygenase, COX-1 and COX-2, enzymes involved in prostaglandin (PG) synthesis. Unlike NSAIDs, Acetaminophen does not inhibit cyclooxygenase in peripheral tissues and, thus, has no peripheral anti-inflammatory affects.

Drug Category
Analgesics; Antipyretics; ATC:N02BE01

Brand Names/Synonyms
4'-Hydroxyacetanilide; 4'-Hydroxyacetanilide, Paracetamol; APAP; Abenol; Abensanil; Acamol; Accu-Tap; Acephen; Aceta; Aceta Elixir; Aceta Tablets; Acetagesic; Acetalgin; Acetaminofen; Acetaminophen; Acetaminophen Uniserts; Actamin; Actamin Extra; Actamin Super; Actimol Chewable Tablets; Actimol Children's Suspension; Actimol Infants' Suspension; Actimol Junior Strength Caplets; Algotropyl; Allay; Alpiny; Alpinyl; Alvedon; Amacodone; Amadil; Aminofen; Aminofen Max; Anacin; Anacin-3; Anacin-3 Extra Strength; Anaflon; Anapap; Anelix; Anexsia; Anexsia 10/660; Anexsia 5/325; Anexsia 7.5/325; Anexsia 7.5/650; Anhiba; Anoquan; Apacet; Apacet Capsules; Apacet Elixir; Apacet Extra Strength Caplets; Apacet Extra Strength Tablets; Apacet Regular Strength Tablets; Apadon; Apamid; Apamide; Apo-Acetaminophen; Arthritis Pain Formula; Aspirin Free Anacin Maximum Strength Caplets; Aspirin Free Anacin Maximum Strength Gel Caplets; Aspirin Free Anacin Maximum Strength Tablets; Aspirin-Free Excedrin Caplets; Atasol Caplets; Atasol Drops; Atasol Forte Caplets; Atasol Forte Tablets; Atasol Oral Solution; Atasol Tablets; Bancap; Bancap Hc; Banesin; Bayer Select Maximum Strength Headache Pain Relief Formula; Bickie-Mol; Bromo Seltzer; Bucet; Butalbital; Butapap; Calpol; Captin; Cetadol; Clixodyne; Co-Gesic; Conacetol; Dafalgan; Dapa; Dapa X-S; Darvocet; Darvocet-N 100; Darvocet-N 50; Datril; Datril Extra-Strength; Dhc Plus; Dimindol; Dirox; Disprol; Dolene Ap-65; Doliprane; Dolprone; Drixoral Plus; Dularin; Duradyne Dhc; Dymadon; Dypap; Elixodyne; Enelfa; Eneril; Esgic; Esgic-Plus; Eu-Med; Excedrin Caplets; Excedrin Extra Strength Caplets; Exdol; Exdol Strong; Febridol; Febrilix; Febrinol; Febro-Gesic; Febrolin; Femcet; Fendon; Feverall; Feverall Junior Strength; Feverall Sprinkle Caps Junior Strength; Fevor; Finimal; Fioricet; Free; G 1; G-1; Gelocatil; Genapap; Genapap Children's Elixir; Genapap Children's Tablets; Genapap Extra Strength Caplets; Genapap Extra Strength Tablets; Genapap Regular Strength Tablets; Genebs; Genebs Extra Strength Caplets; Genebs Regular Strength Tablets; Genebs X-Tra; Hedex; Homoolan; Hy-Phen; Hydrocet; Infants' Feverall; Injectapap; Janupap; Korum; Lestemp; Liquagesic; Liquiprin; Liquiprin Children's Elixir; Liquiprin Infants" Drops; Lonarid; Lorcet-Hd; Lortab; Lyteca; Lyteca Syrup; Meda; Medigesic Plus; Momentum; Multin; Myapap; NAPA; Napafen; Napap; Naprinol; Nealgyl; Nebs; Neopap; Neotrend; Nobedon; Norcet; Norco; O-Acetaminophenol; Oraphen; Oraphen-Pd; Ortensan; Oxycet; Oxycodone 2.5/Apap 500; Oxycodone 5/Apap 500; P-Acetamidophenol; P-Acetaminophenol; P-Hydroxyacetanilide; P-Hydroxyphenolacetamide; Pacemo; Painex; Paldesic; Panadol; Panadol Extra Strength; Panadol Junior Strength Caplets; Panadol Maximum Strength Caplets; Panadol Maximum Strength Tablets; Panaleve; Panasorb; Panets; Panex; Panofen; Papa-Deine #3; Papa-Deine #4; Paracet; Paracetamol; Paracetamol Dc; Paracetamol Ph Eur; Paracetamole; Paracetamolo; Paracetanol; Parapan; Paraspen; Parelan; Parmol; Pasolind; Pasolind N; Pedric; Percocet; Phenaphen; Phenaphen Caplets; Phendon; Phrenilin; Phrenilin Forte; Prompt; Propacet 100; Proval #3; Pyrinazine; Redutemp; Rivalgyl; Robigesic; Rounox; Roxicet; Roxicet 5/500; Roxilox; Salzone; Sedapap; Servigesic; Sk-Apap; Snaplets-Fr; St. Joseph; St. Joseph Fever Reducer; Suppap; Suppap-120; Suppap-325; Suppap-650; Tabalgin; Talacen; Tapanol; Tapanol Extra Strength Caplets; Tapanol Extra Strength Tablets; Tapar; Tavist Allergy/Sinus/Headache; Temlo; Tempanal; Tempra; Tempra Caplets; Tempra Chewable Tablets; Tempra D.S; Tempra Drops; Tempra Syrup; Tencon; Tibinide; Tibizide; Tisin; Tisiodrazida; Tizide; Tralgon; Triad; Triaprin; Tussapap; Tycolet; Tylenol; Tylenol Arthritis Extended Relief; Tylenol Caplets; Tylenol Children's Chewable Tablets; Tylenol Children's Elixir; Tylenol Drops; Tylenol Elixir; Tylenol Extra Strength Adult Liquid Pain Reliever; Tylenol Extra Strength Caplets; Tylenol Extra Strength Gelcaps; Tylenol Extra Strength Tablets; Tylenol Gelcaps; Tylenol Infants Drops; Tylenol Infants" Suspension Drops; Tylenol Junior Strength Caplets; Tylenol Junior Strength Chewable Tablets; Tylenol Regular Strength Caplets; Tylenol Regular Strength Tablets; Tylenol Tablets; Tylox; Tylox-325; Ultracet; Uniserts; Valadol; Valgesic; Valorin; Valorin Extra; Vicodin; Vicodin Es; Vicodin Hp; Wygesic

Dosage Forms
80 mg per mL (OTC) Atasol Drops Panadol Tempra Drops alcohol 10% Tylenol Drops [Generic] 80 mg per 5 mL (OTC) Atasol Oral Solution Panadol sodium Robigesic alcohol 8.5% Tempra Syrup 160 mg per 5 mL (OTC) Tempra Syrup Tylenol Elixir [Generic]

Absorption
Oral _ Rapid and almost complete

Interactions
Interactions for Acetaminophen:

No information provided.

Chemical IUPAC Name
N-(4-hydroxyphenyl)ethanamide

Chemical Formula
C8H9NO2

Half Life
1-4 hours

Drug Type
Approved Drug

# Accession No
APRD00252

CAS Registry Number
103-90-2